Publications by authors named "Masaya Shigeno"

Claim this Profile
F
First Reported Case of Human Infection With Helicobacter cynogastricus.
Mayuko Kakizoe, Tomotaka Mori, Masaya Shigeno, Katsunori Yanagihara, Hisamitsu Miyaaki

Am J Gastroenterol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Viral eradication reduces all-cause mortality in patients with chronic hepatitis C virus infection who had received direct-acting antiviral therapy.
Toshifumi Tada, Masayuki Kurosaki, Hidenori Toyoda, Nobuharu Tamaki, Yutaka Yasui, Masaya Shigeno

Liver Int· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of treatment periods on efficacy of glecaprevir and pibrentasvir in chronic hepatitis C: A nationwide, prospective, multicenter study.
Atsuhiro Morita, Nobuharu Tamaki, Haruhiko Kobashi, Nami Mori, Keiji Tsuji, Masaya Shigeno

JGH Open· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Non-liver-related mortality in the DAA era: Insights from post-SVR patients with and without previous HCC history.
Satoshi Miuma, Hisamitsu Miyaaki, Tatsuki Ichikawa, Toshihisa Matsuzaki, Takashi Goto, Masaya Shigeno

J Med Virol· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of hepatitis C virus eradication after curative treatment for hepatocellular carcinoma in patients with advanced hepatocellular carcinoma and decreased hepatic functional reserve: A nationwide, multicentre study by the Japanese Red Cross Liver Study Group.
Toshie Mashiba, Kouji Joko, Masayuki Kurosaki, Hironori Ochi, Hiroyuki Marusawa, Masaya Shigeno

J Viral Hepat· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluating the Role of Hepatobiliary Phase of Gadoxetic Acid-Enhanced Magnetic Resonance Imaging in Predicting Treatment Impact of Lenvatinib and Atezolizumab plus Bevacizumab on Unresectable Hepatocellular Carcinoma.
Ryu Sasaki, Kazuyoshi Nagata, Masanori Fukushima, Masafumi Haraguchi, Satoshi Miuma, Masaya Shigeno

Cancers (Basel)· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Real-World Data in Japanese Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib from a Nationwide Multicenter Study.
Kaoru Tsuchiya, Masayuki Kurosaki, Azusa Sakamoto, Hiroyuki Marusawa, Yuji Kojima, Masaya Shigeno

Cancers (Basel)· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Liver Function in Older Patients With Unresectable Hepatocellular Carcinoma After Administration of Lenvatinib.
Ryu Sasaki, Masanori Fukushima, Masafumi Haraguchi, Satoshi Miuma, Hisamitsu Miyaaki, Masaya Shigeno

Anticancer Res· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response to Lenvatinib Is Associated with Optimal RelativeDose Intensity in Hepatocellular Carcinoma: Experience in Clinical Settings.
Ryu Sasaki, Masanori Fukushima, Masafumi Haraguchi, Satoshi Miuma, Hisamitsu Miyaaki, Masaya Shigeno

Cancers (Basel)· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world efficacy of elbasvir and grazoprevir for hepatitis C virus (genotype 1): A nationwide, multicenter study by the Japanese Red Cross Hospital Liver Study Group.
Toshie Mashiba, Kouji Joko, Masayuki Kurosaki, Hironori Ochi, Chitomi Hasebe, Masaya Shigeno

Hepatol Res· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world efficacy and safety of sofosbuvir + ribavirin for hepatitis C genotype 2: A nationwide multicenter study by the Japanese Red Cross Liver Study Group.
Takehiro Akahane, Masayuki Kurosaki, Jun Itakura, Keiji Tsuji, Kouji Joko, Masaya Shigeno

Hepatol Res· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rectal Paraganglioma.
Tomonori Araki, Shigeyuki Takeshita, Hiroko Kawasaki, Koichiro Kusumoto, Kazuyuki Ohata, Masaya Shigeno

Intern Med· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Does interferon-free direct-acting antiviral therapy for hepatitis C after curative treatment for hepatocellular carcinoma lead to unexpected recurrences of HCC? A multicenter study by the Japanese Red Cross Hospital Liver Study Group.
Toshie Mashiba, Kouji Joko, Masayuki Kurosaki, Hironori Ochi, Yukio Osaki, Masaya Shigeno

PLoS One· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Management of Pancreatolithiasis: A Nationwide Survey in Japan.
Kazuo Inui, Atsushi Masamune, Yoshinori Igarashi, Hirotaka Ohara, Susumu Tazuma, Masaya Shigeno

Pancreas· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interferon alpha inhibits the nuclear factor kappa B activation triggered by X gene product of hepatitis B virus in human hepatoma cells.
Kazuyuki Ohata, Tatsuki Ichikawa, Kazuhiko Nakao, Masaya Shigeno, Daisuke Nishimura

FEBS Lett· October 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hepatic steatosis is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C virus infection.
Kazuyuki Ohata, Keisuke Hamasaki, Kan Toriyama, Kojiro Matsumoto, Akira Saeki, Masaya Shigeno

Cancer· June 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[A case of extrahepatic portal vein stenosis with portal hypertension, coexisting with arterioportal shunt].
Akira Saeki, Koujirou Matsumoto, Kenji Yanagi, Daisuke Nishimura, Hisayuki Hamada, Masaya Shigeno

Nihon Shokakibyo Gakkai Zasshi· June 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interferon-alpha sensitizes human hepatoma cells to TRAIL-induced apoptosis through DR5 upregulation and NF-kappa B inactivation.
Masaya Shigeno, Kazuhiko Nakao, Tatsuki Ichikawa, Kasumi Suzuki, Atsushi Kawakami

Oncogene· March 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Involvement of IL-1beta and IL-10 in IFN-alpha-mediated antiviral gene induction in human hepatoma cells.
Tatsuki Ichikawa, Kazuhiko Nakao, Keisuke Nakata, Mayumi Yamashita, Keisuke Hamasaki, Masaya Shigeno

Biochem Biophys Res Commun· June 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Aspirin and NS-398 inhibit hepatocyte growth factor-induced invasiveness of human hepatoma cells.
Seigou Abiru, Kazuhiko Nakao, Tatsuki Ichikawa, Kiyoshi Migita, Masaya Shigeno

Hepatology· May 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis